SMALL CELL LUNG CARCINOMA (SCLC)
Clinical trials for SMALL CELL LUNG CARCINOMA (SCLC) explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CARCINOMA (SCLC) trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CARCINOMA (SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes on tough lung cancer
Disease control OngoingThis early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Like drug joins forces with standard chemo to fight lung cancer
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo aims to boost immune attack on tough lung cancers
Disease control OngoingThis early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC